Eli Lilly has entered into a global research collaboration and licensing agreement with Germany-based Seamless Therapeutics to develop and commercialize programmable recombinase based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform.
Seamless’ technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA repair pathway. The company believes the next-gen gene editing approach has broad disease-modifying potential.
Under the terms of the deal, Seamless will design and program site-specific recombinases directed to correct mutations in certain genes of interest related to hearing loss. Lilly will receive an exclusive license to the programmed recombinases to advance through preclinical and clinical drug development and commercialization.
Seamless will receive a guaranteed upfront payment and committed R&D funding. In total, Seamless is eligible for over $1.12 billion, including potential milestone payments, excluding tiered royalties on successfully marketed drugs.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!